# Flow microreactors: review cites linezolid in 27 minutes and 780+ industrial installations

- Published: 2026-11-05 09:25 UTC
- Section: Machines & Making › Manufacturing
- Tags: continuous-flow synthesis, microreactor, drug manufacturing, linezolid synthesis, oseltamivir, modular mini-plant, numbering-up, FDA Q13, process analytical technology, decentralized production
- URL: https://realtech.media/news/rt-4093e95a60c12e012a41f314_flow_microreactors_review/

**A review in The Innovation Insights summarizes a decade of continuous-flow pharmaceutical synthesis and describes a modular container-based plant as the end point of the approach.**

![Flow microreactors: review cites linezolid in 27 minutes and 780+ industrial installations](https://sgzwpqqelzmajkcubgkl.supabase.co/storage/v1/object/public/rt-media/2026/11/1eb2e9865a20f2d3.jpg)
*NASA, Wikimedia Commons, Public domain*

A review published in The Innovation Insights (1(1), 100016) by Oshchepkov, Kochetkov, Pavlov and colleagues concludes that continuous-flow microreactor technology can serve as a blueprint for flexible, decentralized drug manufacturing, according to a 4 November 2026 release on EurekAlert. [1] Conventional plants make medicines batch by batch and stop to isolate and purify intermediates at every step. Flow chemistry instead pumps reagents through millimeter-scale channels under tight control. [1]

## Industrial base and case studies

According to the review, roughly one hundred active pharmaceutical ingredients have been synthesized, at least in part, under continuous-flow conditions. More than 780 industrial microreactor installations operate worldwide, and over 250 chemical companies have adopted microflow technology. Market analyses cited in the release value the microreactor market at about 597.9 million US dollars in 2024. [1]

The case studies include a fully continuous seven-step synthesis of the antibiotic linezolid completed in 27 minutes with a 73 percent isolated yield, compared with more than 60 hours for conventional routes. A ten-step route to oseltamivir gave an overall yield of 58 percent, with reagent residence times of 3.5 minutes. Eli Lilly produced the cancer drug candidate prexasertib under cGMP at 24 kilograms in total, about 3 kilograms per day. Sanofi's semi-continuous artemisinin line produces about 50 to 60 tonnes per year. [1]

## Architecture and limits

The review combines these results into a single scheme. Scale-up is done by parallel numbering-up of reactors rather than by building larger ones. Inline process analytical technology supports quality control, and integrated purification closes the gap between reaction and product: liquid-liquid extraction, membrane separation, scavenger cartridges, continuous chromatography and microfluidic crystallization. The end point is a modular, container-based mini-plant. Analyses cited in the review indicate that modular continuous plants can come online two to three times faster than conventional facilities and raise project net present value by more than 30 percent. [1]

On the regulatory side, FDA guidance Q13 sets out expectations for continuous manufacturing of drug substances and products. [1]

The authors note limits. Continuous flow does not replace batch manufacturing universally: suspended solids can clog channels, very slow reactions lose the advantage, continuous chromatography often sacrifices isolated yield, and membrane separations remain hard to fabricate robustly. Changing an industry built on batch production is capital-intensive, requires retrained specialists and adapted regulatory frameworks. [1]

## Sources

1. [EurekAlert](https://www.eurekalert.org/news-releases/1150460)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-4093e95a60c12e012a41f314_flow_microreactors_review/